Program
bictegravir
Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.
Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.
Drug pageBictegravir: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 238 open or running | phase 4since Oct 23, 2023 | Oct 23, 2014 | Aug 2027phase 2 · NCT07645287 |
| AGC Biologicsits history only | 10 open or running | phase 3since Mar 17, 2010 | Mar 17, 2010 | none ahead |
| Merck | 10 open or running | phase 1since Apr 8, 2026 | Apr 8, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named bictegravirINNProposed as its International Nonproprietary Name in WHO's List 113
- Apr 8, 2026First study: phase 1 study in HealthyFirst studyNCT07532304 · 16 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07532304Healthy · United States | 1 | Completed | Jul 23, 2026 | 16 |
How it is read
Names in the registry
- “B/F/TAF”, 16 entries
- “Bictegravir”, 3 entries
- “BIC/LEN FDC”, 2 entries
- “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
- “Bictegravir/Lenacapavir”, 1 entry
Conditions, from the studies’ own filings
- Coinfection, 1 study
- Kidney Failure, Chronic, 1 study
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.